{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:25:57Z","timestamp":1791498357951,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["BCRF-23-198"],"award-info":[{"award-number":["BCRF-23-198"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2021 SGR 01156"],"award-info":[{"award-number":["2021 SGR 01156"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES21943BRAS"],"award-info":[{"award-number":["INVES21943BRAS"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["847912"],"award-info":[{"award-number":["847912"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105838","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:18:22Z","timestamp":1759303102000},"page":"105838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-9825","authenticated-orcid":false,"given":"E.","family":"Segu\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-3346","authenticated-orcid":false,"given":"E.","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Victoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-5065","authenticated-orcid":false,"given":"C.","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-7264","authenticated-orcid":false,"given":"A.","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Izarzugaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gavil\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-6989","authenticated-orcid":false,"given":"F.","family":"Racca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-9328","authenticated-orcid":false,"given":"K.","family":"Amillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-3364","authenticated-orcid":false,"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"E.","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-7248","authenticated-orcid":false,"given":"B.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mart\u00edn-Liberal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Walbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Indacochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-0166","authenticated-orcid":false,"given":"F.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-1037","authenticated-orcid":false,"given":"\u00c1.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Sirenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-7037","authenticated-orcid":false,"given":"X.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8796-8812","authenticated-orcid":false,"given":"J.M.","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-7022","authenticated-orcid":false,"given":"A.","family":"Mulero-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-1754","authenticated-orcid":false,"given":"F.","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-3563","authenticated-orcid":false,"given":"R.","family":"Mes\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3691","authenticated-orcid":false,"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2025.105838_bib1","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1002\/onco.13887","article-title":"Systematic review of PD-1\/PD-L1 inhibitors in oncology: from personalized medicine to public health","volume":"26","author":"Chang","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105838_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105838_bib3","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"6349","key":"10.1016\/j.esmoop.2025.105838_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105838_bib5","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"7791","key":"10.1016\/j.esmoop.2025.105838_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"6375","key":"10.1016\/j.esmoop.2025.105838_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105838_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"670","key":"10.1016\/j.esmoop.2025.105838_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo3958","article-title":"Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy","volume":"14","author":"Anagnostou","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105838_bib10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","article-title":"The status of tumor mutational burden and immunotherapy","volume":"3","author":"Anagnostou","year":"2022","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105838_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105838_bib12","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/annonc\/mdy335","article-title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types","volume":"29","author":"Par\u00e9","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105838_bib13","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105838_bib14","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.2217\/fon-2022-0660","article-title":"SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA","volume":"18","author":"Prat","year":"2022","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105838_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105838_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105838_bib17","article-title":"Standardized pathology screening of mature tertiary lymphoid structures in cancers","volume":"103","author":"Vanhersecke","year":"2023","journal-title":"Laby Invest"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105838_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105838_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt1385","article-title":"Direct multiplexed measurement of gene expression with color-coded probe pairs","volume":"26","author":"Geiss","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105838_bib21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105838_bib22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105838_bib23","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1038\/s41467-019-13588-2","article-title":"Genetic determinants of the molecular portraits of epithelial cancers","volume":"10","author":"Xia","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105838_bib24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41467-023-36801-9","article-title":"Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer","volume":"14","author":"Prat","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105838_bib25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105838_bib26","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105838_bib27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.annonc.2022.08.084","article-title":"Leveraging big data of immune checkpoint blockade response identifies novel potential targets","volume":"33","author":"Bareche","year":"2022","journal-title":"Ann Oncol"},{"issue":"6257","key":"10.1016\/j.esmoop.2025.105838_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"6377","key":"10.1016\/j.esmoop.2025.105838_bib29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"6411","key":"10.1016\/j.esmoop.2025.105838_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105838_bib31","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105838_bib32","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.medj.2023.07.006","article-title":"A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials","volume":"4","author":"Hernando-Calvo","year":"2023","journal-title":"Med"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.105838_bib33","article-title":"Atezolizumab in patients (pts) with tumor mutational burden (TMB)\u2013high tumors from the TAPISTRY trial","volume":"42","author":"Dziadziuszko","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105838_bib34","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden\u2013high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105838_bib35","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105838_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaad.2021.04.024","article-title":"Clinical impact of immunotherapy in Merkel cell carcinoma patients: a systematic review and meta-analysis","volume":"87","author":"Garza-Davila","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105838_bib37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability\u2013high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105838_bib38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.2021.39.15_suppl.1006","article-title":"The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130","volume":"39","author":"Emens","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105838_bib39","article-title":"A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer","volume":"5","author":"Altorki","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105838_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40364-021-00308-6","article-title":"Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response","volume":"9","author":"Pabla","year":"2021","journal-title":"Biomark Res"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105838_bib41","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105838_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105838_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001792","article-title":"LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2025.105838_bib44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fimmu.2019.01113","article-title":"Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2025.105838_bib45","doi-asserted-by":"crossref","first-page":"S639","DOI":"10.1016\/j.annonc.2023.09.2195","article-title":"1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)","volume":"34","author":"Prat","year":"2023","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:00:46Z","timestamp":1772895646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925017077"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105838","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105838"}}